Tasigna
Novartis’s Tasigna scores EU approval in paediatric patients
November 20, 2017Sales and Marketing Europe, Novartis, Tasigna, chronic myeloid leukaemia, pharma
Novartis’s Tasigna (nilotinib) has received European Commission approval for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in …
NICE says yes to Tasigna for resistant disease
January 13, 2012Sales and Marketing BMS, Glivec, NICE, Novartis, Tasigna
NICE is recommending Novartis’ Tasigna for chronic myeloid leukaemia patients that can no longer use Glivec. In final guidance it …
NICE recommends two Novartis cancer treatments
December 6, 2011Sales and Marketing Glivec, Novartis, Sprycel, Tasigna
Two of Novartis’ cancer drugs have been recommended by NICE for the first line treatment of chronic myeloid leukaemia (CML) …
New discount persuades NICE to back Novartis’ Tasigna
August 18, 2011Sales and Marketing Glivec, NICE, Sprycel, Tasigna
NICE has recommended Novartis’ Tasigna for use in the NHS after the blood cancer drug’s manufacturer submitted a new patient …
‘Weak’ evidence leads to NICE no for three leukaemia drugs
May 6, 2011Sales and Marketing Glivec, NICE, Sprycel, Tasigna
NICE has not recommended three major drugs for the rare blood cancer chronic myeloid leukaemia. In draft guidance on treating …
Novartis ends phase III trial of Tasigna
April 12, 2011GIST, Glivec, Novartis, Tasigna
Novartis has stopped a late stage study of Tasigna for certain types of stomach cancers after it failed to show …
Melanoma: intense competition to be the next milestone treatment
February 9, 2011Research and Development BRAF V600 mutation, Cancer, Tasigna, cancer research, melanoma, tremelimumab
A flurry of new data has emerged in the recent months from an industry-wide pipeline of cancer drugs which could …
Swiss approval for Novartis’ Tasigna
August 31, 2010Sales and Marketing Novartis, Tasigna, Tekamlo
Novartis’ Tasigna has received its first European approval as a first-line treatment after Swiss authorities green-lighted the blood cancer drug …
Digital Pharma: Novartis rapped for Facebook sharing
August 10, 2010Medical Communications Digital Pharma blog, Facebook, Novartis, Tasigna
Novartis has had its knuckles rapped by the FDA over the company’s use of social media sharing tools. At issue …
New products spur Novartis growth
July 15, 2010Sales and Marketing Novartis, Tasigna
Novartis has posted strong results for the second quarter of the year. The Swiss pharma company posted an 11% rise …
Tasigna more effective than Glivec, says Novartis
June 21, 2010Research and Development, Sales and Marketing Glivec, Novartis, Tasigna, leukaemia
Novartis has gained US approval for Tasigna to be used as a front line treatment for chronic myeloid leukaemia. The …
Latest content
Five Facts about cardiovascular disease
